Selective inhibition of mTORC1 in tumor vessels increases antitumor immunity
Open Access
- 6 August 2020
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 5 (15)
Abstract
A tumor blood vessel is a key regulator of tissue perfusion, immune cell trafficking, cancer metastasis, and therapeutic responsiveness. mTORC1 is a signaling node downstream of multiple angiogenic factors in the endothelium. However, mTORC1 inhibitors have limited efficacy in most solid tumors, in part due to inhibition of immune function at high doses used in oncology patients and compensatory PI3K signaling triggered by mTORC1 inhibition in tumor cells. Here we show that low-dose RAD001/everolimus, an mTORC1 inhibitor, selectively targets mTORC1 signaling in endothelial cells (ECs) without affecting tumor cells or immune cells, resulting in tumor vessel normalization and increased antitumor immunity. Notably, this phenotype was recapitulated upon targeted inducible gene ablation of the mTORC1 component Raptor in tumor ECs (Raptor ECKO ). Tumors grown in Raptor ECKO mice displayed a robust increase in tumor-infiltrating lymphocytes due to GM-CSF–mediated activation of CD103 + dendritic cells and displayed decreased tumor growth and metastasis. GM-CSF neutralization restored tumor growth and metastasis, as did T cell depletion. Importantly, analyses of human tumor data sets support our animal studies. Collectively, these findings demonstrate that endothelial mTORC1 is an actionable target for tumor vessel normalization, which could be leveraged to enhance antitumor immune therapies.Keywords
Funding Information
- Instituto Nacional de Cancerología (CA95004)
- VA Medical Center, Tennessee Valley Health System, Nashville Campus (Merit Award)
- VA Medical Center, Tennessee Valley Health System, Nashville Campus (Research Career Scientist Award)
This publication has 73 references indexed in Scilit:
- GM-CSF Controls Nonlymphoid Tissue Dendritic Cell Homeostasis but Is Dispensable for the Differentiation of Inflammatory Dendritic CellsImmunity, 2012
- Tumor-Derived Granulocyte-Macrophage Colony-Stimulating Factor Regulates Myeloid Inflammation and T Cell Immunity in Pancreatic CancerCancer Cell, 2012
- Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cellsJournal of Experimental Medicine, 2011
- Preclinical therapeutic response of residual metastatic disease is distinct from its primary tumor of originInternational Journal of Cancer, 2011
- GM-CSF–dependent, CD103+ dermal dendritic cells play a critical role in Th effector cell differentiation after subcutaneous immunizationJournal of Experimental Medicine, 2010
- Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1Nature, 2009
- Cytokine-secreting follicular T cells shape the antibody repertoireNature Immunology, 2009
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant MetastasisCancer Cell, 2009
- Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell ImmunityScience, 2008
- GM-CSF mediates autoimmunity by enhancing IL-6–dependent Th17 cell development and survivalJournal of Experimental Medicine, 2008